Tianjin Tanabe Seiyaku to Construct New Production Facility in China

Osaka, Japan, August 6, 2013—Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Michihiro Tsuchiya) announced today that Tianjin Tanabe Seiyaku Co., Ltd., (Head Office: Tianjin), one of its consolidated subsidiaries in China, will construct a new production facility.

The pharmaceutical market in China has been growing rapidly in recent years in line with its economic development. The market's size has now reached the third largest level in the world. The planned new facility is designed to boost production capability at the Chinese subsidiary in response to expanding demand in the Chinese pharmaceutical market, which is expected to see continued rapid growth in view of the advancement of the country's medical technology. The new facility, also aimed at meeting new good manufacturing practice (GMP) standards, will be built at the site of existing facilities of Tianjin Tanabe Seiyaku, with construction slated to begin in August this year.

Mitsubishi Tanabe Pharma has been already engaging in business in China, including production and sales of pharmaceuticals by Tianjin Tanabe Seiyaku and Mitsubishi Pharma (Guangzhou) Co., Ltd. (Head Office: Guangzhou), new drug development by Mitsubishi Pharma Research & Development (Beijing) Co., Ltd. (Head Office: Beijing), and sales of pharmaceuticals by Guangdong Tanabe Pharmaceutical Co., Ltd. (Head Office: Guangzhou). Mitsubishi Tanabe Pharma plans to expand its operations in China further by strengthening its business foundation in the country.

Paving the foundation for expanded overseas operations has been set as one of the strategic challenges under Mitsubishi Tanabe Pharma’s Medium-Term Management Plan 11-15 New Value Creation. China was designated as a priority area for implementing the strategy. Mitsubishi Tanabe Pharma contribute to healthier lives of Chinese people through business activities by subsidiaries operating in China; and we challenge to fulfill the mission of becoming a global research-driven pharmaceutical company that is trusted by communities.
<Outline of new manufacturing facility>
Location: No. 16 MIP Third Road, Micro-Electronics Industrial Park, Tianjin Economic-Technological Development Area, Tianjin, China
Start of construction: August 2013
Completion: March 2015 (planned)
The new facility is slated to begin operation in January 2016.
Scale of new facility: 2-story building (construction area: about 5,800 m², total floor space: about 7,200 m²)
Total construction cost: about ¥1.9 billion (planned)
Designing and construction: Dalian Kaiser Construction Co., Ltd.

External appearance:

<Outline of Tianjin Tanabe Seiyaku>
Corporate name: Tianjin Tanabe Seiyaku Co., Ltd.
Representatives: Chairman Baowei Sun
                     President Norihiko Okada
Foundation: October 1993
Paid-in capital: 16.23 million U.S. dollars
Equity holders: 75.35% by Mitsubishi Tanabe Pharma and 24.65% by Tianjin Lisheng Pharmaceutical Co., Ltd.
Business activities: Production and sales of pharmaceuticals
Annual sales: about ¥3.4 billion (for the year ended in March 2013)
Main products: Herbesser, Tanatril, Cerekinon, Gastrom, Talion
Production capacity: about 200 million tablets (as of the end of March 2013)
No. of employees: 430 (as of the end of March 2013)

<For further information, contact>
Corporate Communications Department
Phone: +81-6-6205-5211